How do we ensure the programmers we have today will meet the business needs of tomorrow?

ISSN： 1757-093X

Source： Pharmaceutical Programming, Vol.4, Iss.1-2, 2011-12, pp. : 39-44

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

'Atypical' antipsychotics: how far have we come?

By Baldessarini R.J.

Trends in Pharmacological Sciences, Vol. 22, Iss. 1, 2001-01 ,pp. : 49-50

Elsevier

Access to resources Recommend Favorite

What are we looking for in new antibacterials and how do we design it?

By Barrett John F Motyl Mary

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 2, 2006-02 ,pp. : 85-88

Informa Healthcare

Access to resources Recommend Favorite

MRSA – what is it, and how do we deal with the problem?

By Barrett John F

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 2, 2005-04 ,pp. : 253-265

Informa Healthcare

Access to resources Recommend Favorite

Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?

Current Pharmaceutical Design, Vol. 8, Iss. 19, 2002-09 ,pp. : 1723-1734

Bentham Science Publishers

Access to resources Recommend Favorite

Antimicrobial resistance - why do we have it and what can we do about it?

By Dougherty T.J. Pucci M.J. Bronson J.J. Davison D.B. Barrett J.F.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1707-1709

Informa Healthcare

Access to resources Recommend Favorite